Topology of the yeast Ras converting enzyme as inferred from cysteine accessibility studies

Emily R Hildebrandt1, Dillon M Davis, John Deaton

  • 1Department of Biochemistry and Molecular Biology, The University of Georgia , Athens, Georgia 30602, United States.

Biochemistry
|August 27, 2013
PubMed

Insights

Ras converting enzyme (Rce1p) is a key anticancer target. This study reveals Rce1p’s structure, showing it has a single N-terminal transmembrane helix and re-entrant helices, with essential residues protected from modification.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Background:

  • Ras converting enzyme (Rce1p) is an endoprotease crucial for post-translational modification of Ras GTPases.
  • Its role in Ras biosynthesis makes Rce1p a significant anticancer target.

Purpose of the Study:

  • To elucidate the topology and structural features of Saccharomyces cerevisiae Rce1p.
  • To investigate the chemical accessibility of cysteine residues and essential functional sites within Rce1p.

Main Methods:

  • Chemical modification assays to assess cysteine accessibility.
  • Analysis of N-terminal and C-terminal reactivity and glycosylation potential.
  • Inference of transmembrane segments and structural domains based on chemical accessibility data.

Main Results:

  • Yeast Rce1p exhibits eight segments protected from chemical modification.
  • Essential functional residues (E156, H194, H248) are chemically inaccessible.
  • Rce1p possesses an odd number of transmembrane spans, with the N-terminus likely in the ER lumen.
  • A topological model proposes a single N-terminal transmembrane helix and re-entrant helices on the cytosolic face.
  • Natural cysteine residues are inaccessible and dispensable for Rce1p activity.

Conclusions:

  • The proposed topological model provides insights into Rce1p structure and membrane integration.
  • The findings exclude a cysteine-based enzymatic mechanism for Rce1p.
  • Understanding Rce1p topology is vital for its development as an anticancer therapeutic target.